[{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Fosgonimeton
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
